Showing 5001-5010 of 8923 results for "".
- Bausch Health Plans IPO of Solta Medical Aesthetics Unithttps://practicaldermatology.com/news/bausch-health-plans-ipo-of-solta-medical-aesthetics-unit/2460880/Bausch Health Companies Inc. is planning to pursue an initial public offering (IPO) of its Solta Medical business. Solta’s portfolio includes the Thermage RF systems, Fraxel laser, Clear + Brilliant laser and VASER ultrasonic systems. The timing of the anticipated IPO, w
- ParaPRO’s Natroba for Scabies Now Availablehttps://practicaldermatology.com/news/parapros-natroba-for-scabies-now-available/2460877/ParaPRO’s Natroba (spinosad) Topical Suspension, 0.9% for scabies is now available. Natroba is the first new scabies drug to be approved by the U.S. Food and Drug Administration (FDA) in more than 30 years. Earlier this year, the company received FDA approval of its supp
- US FDA Approves Saphnelo for Lupushttps://practicaldermatology.com/news/us-fda-approves-saphnelo-for-lupus/2460876/The U.S. Food and Drug Administration (FDA) approved Saphnelo (anifrolumab-fnia) as a treatment for adults with systemic lupus erythematosus (SLE) who are receiving standard therapy. Developed by AstraZeneca, Saphnelo is a monoclonal antibody administered by intravenous (IV)
- Hot Off the Press: Dr. Brooke Jackson’s New Book “Skin Care for Runners” Now Availablehttps://practicaldermatology.com/news/hot-off-the-press-dr-brooke-jacksons-new-book-skin-care-for-runners-now-available/2460875/Durham, NC-based dermatologist Dr. Brooke Jackson’s new book, “Skin Care for Runners”, is now available. The book is the definitive guide to healthy skin and nails for runners—and all athletes. In it, Dr. Jackson, also marathoner, offers tips and
- FDA Approves of Sol Gel's Twyneo for Acnehttps://practicaldermatology.com/news/fda-approves-of-sol-gels-twyneo-for-acne/2460874/The FDA has approved Sol Ge's first proprietary drug product, TWYNEO (tretinoin/benzoyl peroxide) cream, 0.1%/3%, for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older. TWYNEO uses Sol-Gel’s patented technology to entrap tretinoin, a retinoid, a
- Dr. James Q. Del Rosso Named Senior Vice President of Clinical Research and Strategic Development at Advanced Dermatology and Cosmetic Surgeryhttps://practicaldermatology.com/news/dr-james-q-del-rosso-named-senior-vice-president-of-clinical-research-and-strategic-development-at-advanced-dermatology-and-cosmetic-surgery/2460873/James Q. Del Rosso, DO is now Senior Vice President of Clinical Research and Strategic Development at Advanced Dermatology and Cosmetic Surgery (ADCS). Dr. James Del Rosso and Ms. Allison Lynch, Chief Operating Officer of Pathology and Research Divisions, will oversee the company’
- Survey: Cleansing Habits of Americans Are Not Up to Dermatologist Standardshttps://practicaldermatology.com/news/survey-cleansing-habits-of-americans-are-not-up-to-dermatologist-standards/2460871/Fully 91 percent of consumers agree that cleansing is important, only 23 percent say that a dermatologist would be pleased with their facial cleansing habits, according to a new survey conducted by CeraVe of 2,000 U.S. adults aged 18-40. This is why this CeraVe is helping
- FDA Delays Review of Pfizer’s Abrocitinib and Xeljanz Filingshttps://practicaldermatology.com/news/fda-delays-review-of-pfizers-abrocitinib-and-xeljanz-filings/2460870/The U.S. Food and Drug Administration (FDA) will not meet the Prescription Drug User Fee Act (PDUFA) goal dates for the New Drug Application for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis and the supplemental New Drug Application for Xeljanz/
- Allergan Aesthetics Continues Partnership with Girls Inc.https://practicaldermatology.com/news/allergan-aesthetics-continues-partnership-with-girls-inc/2460869/Allergan Aesthetics is starting its third consecutive year of partnership with Girls Inc. and debuting Empowering Confidence Workshops, a nationwide mentoring initiative. Based on a 2020 Girls Inc. report, many girls have a hard time picturing themselves in science, technology, eng
- PASI-HD: Modification to PsO Severity Scale Aims at Mild-to-Moderate Diseasehttps://practicaldermatology.com/news/pasi-hd-modification-to-pso-severity-scale-aims-at-mild-to-moderate-disease/2460867/A new modification to the Psoriasis Area and Severity Index (PASI) aims to address limitations of the scale when used to assess mild-to-moderate disease. PASI-high discrimination (PASI-HD), designed to be used in clinical trials among patients for whom the areas of affected body surface are less